Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jürgen Moll

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Cell Cycle (Georgetown, Tex.)|May 19, 2009
Is there a world outside mitosis for Aurora A kinase?Jürgen Moll
Expert Opinion on Therapeutic Targets|December 14, 2007
Aurora kinase inhibitors: identification and preclinical validation of their biomarkersPatrizia Carpinelli, Jürgen Moll
Advances in Experimental Medicine and Biology|July 3, 2008
Aurora kinases and their inhibitors: more than one target and one drugPatrizia Carpinelli, Jürgen Moll
Molecular Diagnosis & Therapy|April 22, 2008
Target validation to biomarker development: focus on RNA interferenceRiccardo Colombo, Jürgen Moll
Drug Discovery Today. Technologies|May 23, 2014
Drug resistanceGemma Texidó, Jürgen Moll
Expert Opinion on Therapeutic Targets|February 15, 2011
Targeting aneuploid cancer cellsRiccardo Colombo, Jürgen Moll
Molecular Diagnosis & Therapy|April 22, 2008
Target validation and biomarker identification in oncology : the example of aurora kinasesRiccardo Colombo, Jürgen Moll
Current Opinion in Drug Discovery & Development|June 30, 2009
Is there a future for Aurora kinase inhibitors for anticancer therapy?Patrizia Carpinelli, Jürgen Moll
Current Drug Targets|September 16, 2010
Destabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cellsRiccardo Colombo, Jürgen Moll
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2010
Targeting cell division cycle 7 kinase: a new approach for cancer therapyAlessia Montagnoli, Jürgen Moll, Francesco Colotta
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Cell Cycle (Georgetown, Tex.)|May 19, 2009
Is there a world outside mitosis for Aurora A kinase?Jürgen Moll
Expert Opinion on Therapeutic Targets|December 14, 2007
Aurora kinase inhibitors: identification and preclinical validation of their biomarkersPatrizia Carpinelli, Jürgen Moll
Advances in Experimental Medicine and Biology|July 3, 2008
Aurora kinases and their inhibitors: more than one target and one drugPatrizia Carpinelli, Jürgen Moll
Molecular Diagnosis & Therapy|April 22, 2008
Target validation to biomarker development: focus on RNA interferenceRiccardo Colombo, Jürgen Moll
Drug Discovery Today. Technologies|May 23, 2014
Drug resistanceGemma Texidó, Jürgen Moll
Expert Opinion on Therapeutic Targets|February 15, 2011
Targeting aneuploid cancer cellsRiccardo Colombo, Jürgen Moll
Molecular Diagnosis & Therapy|April 22, 2008
Target validation and biomarker identification in oncology : the example of aurora kinasesRiccardo Colombo, Jürgen Moll
Current Opinion in Drug Discovery & Development|June 30, 2009
Is there a future for Aurora kinase inhibitors for anticancer therapy?Patrizia Carpinelli, Jürgen Moll
Current Drug Targets|September 16, 2010
Destabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cellsRiccardo Colombo, Jürgen Moll
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2010
Targeting cell division cycle 7 kinase: a new approach for cancer therapyAlessia Montagnoli, Jürgen Moll, Francesco Colotta
Pageof 4